The results of the Q-SYMBIO trial showing a reduction in mortality in patients with heart failure treated with coenzyme Q10 have substantial limitations. Nevertheless, they highlight the need to identify effective new therapies targeted at mitochondrial dysfunction and oxidative stress in heart failure.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mitochondrial function as a therapeutic target in heart failure
Nature Reviews Cardiology Open Access 22 December 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–e239 (2013).
Mortensen, S. A. et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. http://dx.doi.org/10.1016/j.jchf.2014.06.008.
Burgoyne, J. R., Mongue Din, H., Eaton, P. & Shah, A. M. Redox signaling in cardiac physiology and pathology. Circ. Res. 111, 1091–1106 (2012).
Oka, T. et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485, 251–255 (2012).
Lygate, C. A. & Neubauer, S. Metabolic flux as a predictor of heart failure prognosis. Circ. Res. 114, 1228–1230 (2014).
Hare, J. M. et al. Impact of oxypurinol in patients with symptomatic heart failure. Results from the OPT-CHF study. J. Am. Coll. Cardiol. 51, 2301–2309 (2008).
Ernster, L. & Dallner, G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta 1271, 195–204 (1995).
McMurray, J. J. V. et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J. Am. Coll. Cardiol. 56, 1196–1204 (2010).
O'Connor, C. M. et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301, 1439–1450 (2009).
Dai, D. F. et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J. Am. Coll. Cardiol. 58, 73–82 (2011).
Acknowledgements
The authors are supported by funding from the British Heart Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Okonko, D., Shah, A. Mitochondrial dysfunction and oxidative stress in CHF. Nat Rev Cardiol 12, 6–8 (2015). https://doi.org/10.1038/nrcardio.2014.189
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.189
This article is cited by
-
Mitochondria as a therapeutic target for common pathologies
Nature Reviews Drug Discovery (2018)
-
Pterostilbene Decreases Cardiac Oxidative Stress and Inflammation via Activation of AMPK/Nrf2/HO-1 Pathway in Fructose-Fed Diabetic Rats
Cardiovascular Drugs and Therapy (2018)
-
Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials
Current Heart Failure Reports (2018)
-
Mitochondrial function as a therapeutic target in heart failure
Nature Reviews Cardiology (2017)
-
Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
Archives of Toxicology (2015)